Clinical Trial Update: A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CCX140-B on urinary albumin excretion in adults with type 2 diabetes and albuminuria has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• CCX140-B (CCX140-B)

Snippet

Sponsor: Amgen | Conditions: Diabetic Nephropathy, Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED